AstraZeneca shares jumped nearly 7% on Friday, on course for their biggest one-day gain in about a year, after third-quarter profit came in well ahead of forecasts. Core earnings per share of $2.79 beat the $2.59 analysts expected, revenue rose 7% to $16.2bn and cancer drug sales grew 17%. The rally reversed losses from earlier in the year.
The company also kept its full-year targets and set out a three-year cost programme, and its chief executive struck an upbeat tone on the drugs it expects to read out next year. The shares were trading nearly 7% higher by 13:52 GMT, according to Reuters, building on a 3.04% gain in the week to 23 October, when they closed at £128.24.
Third quarter, 2026
- $2.79 core EPS, against $2.59 forecast
- $16.2bn revenue, up 7% at constant currency
- +17% oncology revenue, to $7.77bn
A Clean Beat on Profit and Sales
Revenue of $16.21bn compared with analysts' forecasts of $15.94bn, according to Reuters. Core EPS rose 19% at constant exchange rates. Reported EPS was $2.02.
For the first nine months, revenue reached $46.9bn, up 7% at constant currency, and core EPS was $8.00, up 14%. By therapy area, oncology brought in $21.9bn over the nine months, up 16%, and rare disease $7.5bn, up 11%. The BioPharmaceuticals unit, which covers respiratory and immunology, cardiovascular, renal and metabolism (CVRM) and infectious disease medicines, fell 5% to $16.7bn, with CVRM down 14%.
Operating expenses for the nine months were $27.56bn, up 7%, and the company said costs would rise again in the fourth quarter, in line with the usual seasonal pattern.

AstraZeneca: share price, chart and news
Cancer Drugs Carry the Quarter
Oncology is now close to half of group sales, and it drove the beat. The main products moved like this in the third quarter:
| Medicine | Q3 2026 sales | Change |
|---|---|---|
| Oncology total | $7.77bn | +17% |
| Imfinzi (immunotherapy) | about $2.0bn | +26% |
| Enhertu (breast and other cancers) | $969m | +35% |
| Farxiga (diabetes, heart, kidney) | $1.61bn | -25% |
Farxiga is the weak spot. Its sales fell by a quarter after the medicine lost exclusivity, which the company listed as a headwind alongside Brilinta's loss of exclusivity and volume-based procurement in China.
Markets: indices, currencies and commodities
Guidance Held and a $1.5bn Savings Plan
AstraZeneca reconfirmed its 2026 guidance: total revenue up by a mid-to-high single-digit percentage and core EPS up by a low double-digit percentage, both at constant exchange rates. The core tax rate is expected at 18% to 22%.
It also set out a three-year efficiency programme running to 2029. It is expected to produce about $1.5bn of annual savings by then, mostly to be put back into a pipeline of more than 180 projects, and to cost up to $2bn in one-off restructuring charges. The company gave few details and did not say whether jobs would be cut.
The longer target is unchanged: $80bn of annual revenue by 2030, helped by about 20 new medicines it expects to launch. So far it has delivered 14 of those 20. Chief executive Pascal Soriot said the group is "on track to deliver our 2030 ambition".
Why the Market Cared: 2027 Readouts
The quarter ends a difficult stretch for the shares. Earlier in the year a trial miss and talk of a deal involving Bristol Myers Squibb weighed on the stock, and there were recent setbacks for camizestrant and Wainua.
AstraZeneca has had 12 positive Phase III readouts so far this year, and it listed four newly approved medicines in its results. Soriot pointed investors to a series of late-stage trial results due in 2027, which together could support more than $20bn of peak annual sales.
What investors watch now
- Fourth-quarter costs, which the company says will rise with the usual seasonal pattern.
- Whether Farxiga's generic decline keeps BioPharmaceuticals sales falling.
- Details of the 2029 savings programme, including any job cuts.
- The 2027 Phase III readouts, which analysts say are now the main focus for the shares.
Full-year results will show whether the company lands inside its reconfirmed range, and how much of the restructuring charge it books early.
Sources
- AstraZeneca: 9M and Q3 2026 results
- Devdiscourse (Reuters): AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
- BMK News market data (delayed exchange data)








